Description
The TLD-3A12 antibody specifically recognizes CD31, also known as PECAM-1 (platelet endothelial cell adhesion molecule). CD31 is a ~130 kDa integral membrane glycoprotein, a member of the immunoglobulin superfamily, that mediates homophilic and heterophilic cell-cell adhesion. CD31 is expressed on endothelial cells, platelets, and subsets of leucocytes. In the human and mouse, multiple alternatively spliced isoforms have been identified, and this alternative splicing may be involved in the regulation of ligand specificity. CD31-mediated endothelial cell-cell interactions are involved in angiogenesis in the mouse and rat. In addition, PECAM-1 has been demonstrated to play an important role in extravasation of leucocytes in vivo, but in vivo treatment with TLD-3A12 mAb had no discernable effect upon the inflammatory infiltrate in experimental allergic encephalomyelitis. The TLD-3A12 mAb partially blocks the proliferative response of antigen-specific CD4+ T cells to antigen-presenting cells and relevant antigen. This mouse anti-rat CD31 antibody crossreacts with pig endothelial cells and platelets, as determined by immunohistochemical staining of acetone-fixed frozen sections and immunofluorescent staining with flow cytometric analysis, respectively. A suspension of Lewis rat microglial cells was used as the the immunogen.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome-conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBeads. This will ensure that BD CompBeads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385). Note: When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed. For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. An isotype control should be used at the same concentration as the antibody of interest.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
5. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. CF™ is a trademark of Biotium, Inc.
8. BD Horizon Brilliant Ultraviolet 563 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
9. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
